Details of the Drug Combination

General Information of Drug Combination (ID: DCDKTRM)

Drug Combination Name
ABIRATERONE Indazole derivative 5
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs ABIRATERONE   DM8V75C Indazole derivative 5   DMM1I8R
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: K-562
Zero Interaction Potency (ZIP) Score: 6.47
Bliss Independence Score: 9.56
Loewe Additivity Score: 3.73
LHighest Single Agent (HSA) Score: 9.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [4]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DC9XTHR U251 Investigative [1]
Clear cell renal cell carcinoma DCVHE9C CAKI-1 Investigative [1]
Papillary renal cell carcinoma DCND3JP ACHN Investigative [1]
Breast adenocarcinoma DC98QNJ MDA-MB-468 Investigative [5]
Colon adenocarcinoma DC2D5HA COLO 205 Investigative [5]
Invasive ductal carcinoma DCDHIOL BT-549 Investigative [5]
Invasive ductal carcinoma DCLYH34 T-47D Investigative [5]
Adenocarcinoma DC7QNJW DU-145 Investigative [6]
Adenocarcinoma DCNNQHL NCIH23 Investigative [6]
Adenocarcinoma DCWLZZW HCT116 Investigative [6]
Amelanotic melanoma DCAOS0W M14 Investigative [6]
Cutaneous melanoma DC9F1R4 SK-MEL-28 Investigative [6]
High grade ovarian serous adenocarcinoma DCHFFFZ NCI\\/ADR-RES Investigative [6]
Large cell lung carcinoma DCCJLTZ NCI-H460 Investigative [6]
Lung adenocarcinoma DCEWESD HOP-62 Investigative [6]
Melanoma DC1W04T SK-MEL-2 Investigative [6]
Melanoma DCI54IX UACC-257 Investigative [6]
Minimally invasive lung adenocarcinoma DCONUQQ NCI-H322M Investigative [6]
Ovarian serous cystadenocarcinoma DCRUCY9 SK-OV-3 Investigative [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
4 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
6 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976